Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Rating) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$1.88 and traded as high as C$2.57. Oncolytics Biotech shares last traded at C$2.53, with a volume of 42,640 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Maxim Group reissued a “buy” rating and issued a C$3.00 price objective on shares of Oncolytics Biotech in a report on Thursday, October 6th.
Oncolytics Biotech Trading Up 1.6 %
The company has a quick ratio of 8.86, a current ratio of 10.42 and a debt-to-equity ratio of 1.62. The company has a fifty day moving average of C$2.27 and a two-hundred day moving average of C$1.88. The stock has a market capitalization of C$149.34 million and a price-to-earnings ratio of -5.25.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.